Echocardiographic assessment with right ventricular function improvement following ultrasound-accelerated catheter-directed thrombolytic therapy in submassive pulmonary embolism
- PMID: 28945166
- DOI: 10.1177/1708538117733645
Echocardiographic assessment with right ventricular function improvement following ultrasound-accelerated catheter-directed thrombolytic therapy in submassive pulmonary embolism
Abstract
Introduction The objective of this study was to evaluate the efficacy of ultrasound-accelerated catheter-directed thrombolytic therapy in patients with submassive pulmonary embolism. Methods Clinical records of 46 patients with submassive pulmonary embolism who underwent ultrasound-accelerated catheter-directed pulmonary thrombolysis using tissue plasminogen activator, from 2007 to 2017, were analyzed. All patients experienced clinical symptoms with computed tomography evidence of pulmonary thrombus burden. Right ventricular dysfunction was present in all patients by echocardiographic finding of right ventricle-to-left ventricle ratio > 0.9. Treatment outcome, procedural complications, right ventricular pressures, and thrombus clearance were evaluated. Follow-up evaluation included echocardiographic assessment of right ventricle-to-left ventricle ratio at one month, six months, and one year. Results Technical success was achieved in all patients ( n = 46, 100%). Our patients received an average of 18.4 ± 4.7 mg of tissue plasminogen activator using ultrasound-accelerated thrombolytic catheter with an average infusion time of 16.5± 5.4 h. Clinical success was achieved in all patients (100%). Significant reduction of mean pulmonary artery pressure occurred following the treatment, which decreased from 36 ± 8 to 21 ± 5 mmHg ( p < 0.001). There were no major bleeding complications. All-cause mortality at 30 days was 0%. No patient developed recurrent pulmonary embolism during follow-up. During the follow-up period, 43 patients (93%) showed improvement of right ventricular dysfunction based on echocardiographic assessment. The right ventricle-to-left ventricle ratio decreased from 1.32 ± 0.18 to 0.91 ± 0.13 at the time of hospital discharge ( p < 0.01). The right ventricular function remained improved at 6 months and 12 months of follow-up, as right ventricle-to-left ventricle ratio were 0.92 ± 0.14 ( p < 0.01) and 0.91 ± 0.15 ( p < 0.01), respectively. Conclusion Ultrasound-accelerated catheter-directed thrombolysis is a safe and efficacious treatment for submassive pulmonary embolism. It reduces pulmonary hypertension and improves right ventricular function in patients with submassive pulmonary embolism.
Keywords: Thrombolytic therapy; pulmonary embolism; subacute pulmonary embolism.
Similar articles
-
Ultrasound-accelerated catheter-directed thrombolysis for acute submassive pulmonary embolism.J Vasc Interv Radiol. 2015 Jul;26(7):1001-6. doi: 10.1016/j.jvir.2014.12.017. Epub 2015 Feb 18. J Vasc Interv Radiol. 2015. PMID: 25704224
-
Thrombus resolution and right ventricular functional recovery using ultrasound-accelerated thrombolysis in acute massive and submassive pulmonary embolism.Int Angiol. 2017 Oct;36(5):428-437. doi: 10.23736/S0392-9590.17.03775-0. Epub 2017 Feb 15. Int Angiol. 2017. PMID: 28206731
-
Ultrasound-assisted thrombolysis in submassive and massive pulmonary embolism: assessment of lung obstruction before and after catheter-directed therapy.Cardiovasc Intervent Radiol. 2014 Apr;37(2):420-6. doi: 10.1007/s00270-013-0696-x. Epub 2013 Jul 17. Cardiovasc Intervent Radiol. 2014. PMID: 23860937
-
Meta-Analysis of Catheter Directed Ultrasound-Assisted Thrombolysis in Pulmonary Embolism.Am J Cardiol. 2019 Nov 1;124(9):1470-1477. doi: 10.1016/j.amjcard.2019.07.040. Epub 2019 Aug 7. Am J Cardiol. 2019. PMID: 31492420 Review.
-
Thrombolytic therapy for submassive pulmonary embolism.Best Pract Res Clin Haematol. 2012 Sep;25(3):379-89. doi: 10.1016/j.beha.2012.06.005. Epub 2012 Aug 4. Best Pract Res Clin Haematol. 2012. PMID: 22959553 Review.
Cited by
-
[Ultrasound-accelerated thrombolysis. Initial experience in patients with contraindications to systemic thrombolysis].Rev Med Inst Mex Seguro Soc. 2023 May 2;61(3):370-379. Rev Med Inst Mex Seguro Soc. 2023. PMID: 37216692 Free PMC article. Review. Spanish.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical